Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Solid TumorCentral Nervous System TumorLymphomaLeukemia
Interventions
DRUG

Neratinib

Neratinib will be administered orally, or through existing gastrostomy feeding tube, once a day with food, preferably in the morning, continuously for 28-day cycles, with no rest between cycles. Dose will be scaled by body surface area (BSA).

Trial Locations (9)

10065

Memorial Sloan Kettering Cancer Center, New York

17033

Pennsylvania State Hershey Children's Hospital, Hershey

32806

Arnold Palmer Hospital for Children, Orlando

72206

Arkansas Children's Hospital, Little Rock

78229

University of Texas, San Antonio

84113

Huntsman Cancer Institue, Salt Lake City

85016

Phoenix Children'S Hospital, Phoenix

94304

Stanford University School of Medicine and Stanford Cancer Institute, Palo Alto

T3B 6A8

Alberta Children'S Hospital, Calgary

All Listed Sponsors
collaborator

Milton S. Hershey Medical Center

OTHER

collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

Stanford University

OTHER

collaborator

Arkansas Children's Hospital Research Institute

OTHER

collaborator

Alberta Children's Hospital

OTHER

collaborator

Phoenix Children's Hospital

OTHER

collaborator

University of Texas

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02932280 - Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment | Biotech Hunter | Biotech Hunter